DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

VX-152 + tezacaftor+ ivacaftor

Phase Two

Phase Two

Therapeutic Approach

Restore CFTR Function

This program is testing VX-152 in combination with tezacaftor and ivacaftor. VX-152 and tezacaftor (VX-661) are new CFTR correctors. Correctors are drugs designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Once CFTR protein reaches the cell surface, ivacaftorhelps facilitate the opening of the chloride channel to allow chloride and sodium (salt) to move inand out of the cell.

Status

A phase 2 study for people with CF who have two copies of the F508del CFTR mutation, or one copy of F508del and one copy of a minimal function CFTR mutation, will begin soon.

Sponsor

This program is sponsored by Vertex Pharmaceuticals and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT).This program is being conducted within CFFT's Therapeutics Development Network (TDN).

Contact us about VX-152 + tezacaftor+ ivacaftor >